Zimmer Biomet Holdings Income Statement 2025-2006 | ZBH

Brief overview of profit and loss at Zimmer Biomet Holdings

This overview is based on financial performance over the past five years. Revenue reported by Zimmer Biomet Holdings was 6.1 billion dollars at the beginning of the period and 8.2 billion dollars at the end. The cumulative result was +34.3%, corresponding to roughly 6.1% per year. Sales increased steadily, although without strong acceleration.

Gross profit was $4.3 billion at the start and $5.7 billion at the end of the period (+33.3%). The relationship between revenue and direct costs remained stable. Comparing the endpoints gives gross margins of 70.2% and 69.7%. The gross margin stayed within a similar range.

EBITDA changed from $982 million to $2.2 billion (+123.3%). Operating profitability strengthened faster than the scale of sales. Comparing the endpoints gives EBITDA margins of 16% and 26.6%. The increased EBITDA share is a positive sign.

The final result was −$139 million initially and $705 million in the final year. The trajectory reversed from a loss to positive earnings.

Market value was 30.7 billion dollars at the start and 16.3 billion dollars at the end. Investors remain cautious despite better financial results.

Overall conclusion

Positive developments coexist with areas of weakness. The financial profile benefits from revenue expansion, higher operating efficiency and consistent sales economics. Caution is warranted because of declining capitalization. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.